The interplay between antidiabetic medications and cancer risk
Authors:
Open Access
- 23 October 2023
- journal article
- research article
- Published by Medip Academy in International Journal of Scientific Reports
- Vol. 9 (11) , 384-385
Abstract
Diabetes mellitus (DM) refers to a group of metabolic disorders marked by chronic hyperglycemia. Its primary cause usually involves impaired insulin secretion or impaired insulin action. Its prevalence is escalating globally. Type II DM (T2DM) is becoming more common, and it is expected to afflict 7.7% (439 million) of persons aged 20 to 79 by 2030. Diabetes appears to be linked to an increased risk of a variety of cancers, ranging from a 20 to 30% greater risk of breast or colorectal cancer to a 97% increased chance of intrahepatic cholangiocarcinoma or endometrial cancer. Shared risk factors and potential biochemical pathways have prompted investigations into the effect of antidiabetic medications (ADMs) on cancer risk. We intend to investigate the link between diabetes drugs and cancer development.Keywords
This publication has 8 references indexed in Scilit:
- The interplay between antidiabetic medications and cancer riskInternational Journal of Scientific Reports, 2023
- Diabetes medications and cancer risk associations: a systematic review and meta-analysis of evidence over the past 10 yearsScientific Reports, 2023
- Treatment of type 2 diabetes mellitus and risk of pancreatic cancerEndokrynologia Polska, 2021
- The Influence of Anti-Diabetic Drugs on Prostate CancerCancers, 2021
- Definition, Classification and Diagnosis of Diabetes MellitusExperimental and Clinical Endocrinology & Diabetes, 2019
- Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes AssessmentDiabetes & Metabolism Journal, 2019
- Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 StudiesScientific Reports, 2015
- Global estimates of the prevalence of diabetes for 2010 and 2030Diabetes Research and Clinical Practice, 2010